Inhalation product development

Skyepharma’s inhalation product development laboratories in Switzerland have an excellent track record of successful development of inhaled products from initial concept to commercial manufacture and supply. This reputation was further strengthened by the approval and subsequent launch of flutiform® in Europe and Japan, building on previous Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) approvals. Products developed by our team have been approved in over 30 countries worldwide, including in Europe and the US.

In all of our development programmes we adopt a Quality by Design (QbD) approach, applying and challenging possible technologies and techniques in order to deliver the optimal product profile and performance in a timely and efficient manner. This has resulted in the successful development of a range of different inhalation products, from early stage API characterisation, formulation and analytical development through to process development, scale-up and technology transfer for commercial manufacture. We also have considerable know-how in the design, development and commercialisation of inhalation devices.

Our team has recent experience of the regulatory requirements for approval of inhalation products in international markets. In this field, up-to-date know-how and expertise is essential.

We welcome the opportunity to discuss inhalation product development opportunities and how our proven expertise and technologies can help reduce the risk and increase the chances of product success.

Contact us if you are interested in discussing potential collaboration.
Find out more about our inhalation product development capabilities and technologies.

Aerosol testing at Skyepharma laboratories

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.